NCT01284049View on ClinicalTrials.gov

Evaluation of OMEGAVEN 10%® (n-3 EFA Lipid Emulsion) in Home Parenteral Nutrition-associated Liver Disease

NACompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

April 30, 2015

Study Completion Date

March 31, 2016

Conditions
Liver Diseases
Interventions
DRUG

Intralipid 20%®

Administration of Intralipid 20%® at a dose ranging between 0.5 and 1 g/kg/infusion during 12 weeks.

DRUG

OMEGAVEN 10%®

OMEGAVEN 10%® will be used as the sole lipid supplement at a dose of 0.5 to 1.0 g/kg/Infusion with a maximum dose per infusion of 40 grams, in view of formulation constraints during 12 weeks.

Trial Locations (1)

92110

Dr Francisca JOLY, Clichy

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT01284049 - Evaluation of OMEGAVEN 10%® (n-3 EFA Lipid Emulsion) in Home Parenteral Nutrition-associated Liver Disease | Biotech Hunter | Biotech Hunter